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Background: Left atrial appendage occlusion with the Amplatzer Cardiac Plug
Device (ACP) (St Jude Medical, Minneapolis, MN) for non valvular atrial ﬁbrilla-
tion(NVAF) and contraindications to oral anticoagulant therapy (OAC) is showing to
be feasible and safe but there is lack of data as for the long term follow up.
Methods: We report the follow up of 134 patients treated with ACP device from 1/
2009 to 12/2012 in two Italian centers. Most patients received short-term (1-3 months)
dual antiplatelet therapy following the procedure and single antiplatelet therapy
thereafter. Follow up was carried out by clinical visits or phone contact at 1, 6 and 12
months and yearly thereafter. A total of 93(72.6%) patients received imaging follow-
up 6 months after the procedure either by transesophageal echography(TEE) or by
cardiac CT scan. The presence of device thrombosis and residual leak were evaluated.
Results: Mean age and median CHADS2 were 768 years and 3 respectively. The
procedure was successful in 96% of the patients. Main complications were pericardial
effusion (4.4%) with 2 cases of cardiac tamponade (1.4%), 1 hemorragic stroke and 1
TIA. Median follow up was 22 months (range 1.4 – 53.6). The longest follow up was 4
years for 4 patients. 26 patients had a follow up of 3 years. 110 patients had a follow up of
>¼12months. The rates of death, stroke, TIA and systemic embolism at follow-up, were
5.5%, 1.5%, 2.3% and 0%, respectively. The presence of peri device leak was observed
in 5.4% of patients at 6-months imaging follow-up. No massive leak was observed.
There was one case of device thrombosis that resolved after 1 month of anticoagulation.
The expected stroke rate was 8.6% versus an observed stroke rate of 1.5% (p<0.01).
Conclusions: Our follow up of patients treated with ACP device for NVAF and
contraindications to OAC demonstrates the efﬁcacy of the procedure in preventing
stroke over a long time period (110 pts followed for >1 year), with a signiﬁcant
reduction of the risk of stroke as compared with the expected incidence. The imaging
follow-up showed low incidence of signiﬁcant residual leaks. We also conﬁrm the
feasibility and safety of the LAAO procedure.
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Background: Percutaneous left ventricular transapical access (TA) can be utilized for
a multitude of diagnostic and interventional procedures in structural heart disease
(SHD). With advancements in imaging and device technology, applicability of this
approach is expanding. We present our growing experience in utilizing TA for
structural heart interventions.
Methods: We evaluated patients at our center, from April 2008 to June 2013, who
presented for SHD intervention. Ninety four TA were performed in 80 consecutive
patients (54 males, 7130 years) with 4 patients having double TA during the same
intervention and 10 patients having repeat TA during subsequent SHD interventions
(double TA n¼13). Since August 2010, computed tomographic angiography (CTA)/
ﬂuoroscopy fusion imaging (HeartNavigator, Philips, Netherlands) has been used to
guide TA puncture.
Results: All TA were successfully performed for the following interventions: 74
mitral paravalvular leak (PVL) closure, 6 aortic PVL closure, 14 left ventricular
pseudoaneurysm (LVPA) closure, 2 ventricular septal defect closure, 8 mitral trans-
catheter valve-in-valve implantations, and 10 combined procedures. Average initial/
ﬁnal sheath sizes were 6F and 7F (range 5F-12F). TA was closed using an Amplatzer
Ductal Occluder n¼86, Amplatzer Vascular Plug II n¼3, Muscular VSD Occluder
n¼3, and coils n¼2. Complications occurred in 13 cases (14%): hemothorax n¼5,
pericardial effusion/tamponade n¼1; persistent access site bleeding requiring surgical
closure n¼2, non-fatal device migration n¼3 (2 ventricular, 1 epicardial requiring
surgical closure), and death n¼2. One death occurred in a patient with suprasystemic
pulmonary hypertension developing pulseless electrical activity and one death
occurred after PVL closure in the setting of untreated critical aortic stenosis and
epicardial device migration. There was no signiﬁcant difference in complications
associated with use of fusion imaging (with 10% vs without 17.6%, p¼0.29).
Conclusions: TA is useful in multiple SHD interventions. Despite fusion imaging,
complications still occur. More reliable TA closure devices may further improve the
safety and generalizabilty of this approach for more complex SHD interventions.B32 JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT ATCT-99
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Background: Patients with a patent foramen ovale (PFO) and a history of paradoxical
embolism are at risk to suffer from recurrent events even if the PFO was closed
percutaneously. This study investigated the long-term results of a high-volume center.
Methods: PFOs were closed in patients with a history of at least one assumed para-
doxical embolism (TIA, stroke or peripheral embolism) or a diving accident. The type of
closure device was chosen due to availability and operator's decision. All patients were
prescribed a dual antiplatelet therapy (aspirin and clopidogrel) for the ﬁrst 6months after
the procedure. Echocardiographic studies were performed at 4 weeks and 6 months after
the index procedure. Patients were evaluated for residual shunts and the incidence of
potential adverse events. All patients were followed annually through ofﬁce visits,
questionnaires and phone calls, or by contacting the referring physicians.
Results: Between August 1998 and December 2012 percutaneous closure of patent
foramen ovale was performed in 2831 patients. The mean age of patients was 50  13
years. 55% were male (n¼1551). Indication for PFO-closure was a history of migraine
(n¼481), peripheral embolism (n¼55), diving accident (n¼36) or cryptogenic cerebral
ischemia (TIA in n¼1334 or stroke in n¼1666). 563 patients (19.9%) suffered from
recurrent neurological events before percutaneous PFO-closure. We used 23 different
types of closure devices. The most commonly used occluders were the Amplatzer
(n¼914), the Helex (n¼470), the Premere (n¼409) and the CardioSEAL-STARﬂex
device (n¼303). Within a total of 8,873 patient years of follow-up (mean follow-up
duration: 38 months), there were 89 recurrent embolic events. This compares to an
annual event rate of 1.0%. 29 patients suffered from recurrent TIA, and in 54 patients
an ischemic strokes occurred. In 6 patients peripheral embolic events occurred. In 122
patients (4.3%) a second device implantation was performed to close a residual shunt.
Conclusions: The results of this study represent the clinical experience of a European
high-volume center in PFO-closure and show a favorable and much lower annual
recurrent event rate compared to previously published randomized trials.
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Background: We assessed the predictors of length of hospital stay (LOS) and cost of
care related to percutaneous closure of ASD and PFO closure.
Methods: We examined the Healthcare Cost and Utilization Project's Nationwide
Inpatient Sample (NIS) database from 2001 to 2010 using ICD 9-CM code for
percutaneous ASD/PFO closure (35.52). Only adult (age > 18 year) patients with
ASD/PFO (ICD 9-CM - 745.5) were included in study. We could not differentiate
between ASD and PFO closure due to the same ICD9 code for both procedures. NIS is
represents 20% of all US hospitals. Cost to charge ratio ﬁles were merged with NIS to
calculate cost of care. Cost was adjusted for inﬂation in reference to 2010. Comorbid
conditions were deﬁned by Charlson's Comorbidity Index (CCI). Hierarchical
multilevel regression models were generated to determine independent predictors of
LOS and cost of care.
Results: Total of 7,107 (weighted n¼34,990) percutaneous ASD/PFO closure
procedures were analyzed. Average LOS and cost of care for percutaneous ASD/PFO
closure were 2.630.06 days and $16,635225, respectively. LOS was increased
(days, 95% CI, P-value) with presence of any complication (+2.47 days, 2.14-2.80,
P 2 (+1.84 days, 1.48-2.20, P<0.001). Decrease in LOS was associated with use
of higher operator volume tertile(-2.58 days, -3.04 - -2.12, P2) (1.17, 1.12-1.22,
P<0.001). Decrease in cost was associated with higher annual operator volume tertile
(0.84, 0.08 - 0.88, P<0.001).bstracts/ORAL/Percutaneous Treatment of Non-valvular Structural Heart Disease
Baseline Post procedure P value
BPA (n[25) CO (L/min) 3.57  0.91 4.44  1.11 0.007
mPAP (mmHg) 39.1  6.9 22.5  4.9 <0.0001
PVR
(dynes/s/cm-5)
746  304 295  117 <0.0001
6MWD (m) 302  100 380  113 0.0004
WHO Fc
(I/II/III/IV)
(0/2/16/7) (10/11/3/0) 0.0009
PEA (n[21) CO (L/min) 3.35  1.20 4.62  1.67 0.007
mPAP (mmHg) 44.6  12.0 23.2  6.2 <0.0001
PVR
(dynes/s/cm-5)
785  291 267  134 <0.0001
6MWD (m) NA NA
WHO Fc
(I/II/III/IV)
(0/1/13/7) (11/7/1/0) 0.0007
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SConclusions: In conclusion, ICE use and high operator volume are signiﬁcant
predictors of improved out come in ASD/PFO closure.
TCT-101
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Background: Left ventricular pseudoaneurysms (LVPAs) may occur as sequelae of
cardiac surgery, myocardial infarction (MI), or endocarditis, and may result in
congestive heart failure (CHF) or rupture with sudden death. Percutaneous closure of
LVPAs has been reported but long-term outcomes are unknown.
Methods:We reviewed all patients who underwent percutaneous LVPA closure at our
center from 09/2008 to 02/2013. All patients had a pre-procedural helical CTA. LVPA
size was measured on CTA in 3 perpendicular planes (x,y, and z), with x-plane being
the largest diameter and y-plane being the largest perpendicular diameter. Clinical
followup was obtained in all patients with assessment of survival and CHF. Followup
CTA studies were reviewed to assess residual LVPA ﬂow.
Results: 15 LVPA closures were performed in 14 patients (mean age 72; male 71%;
CHF 79%, mean NYHA class 2.6). The etiology was post-surgical in 11 cases, post-
MI in 2 cases, and endocarditis in 1 case. 10 had associated paravalvular leaks. The
mean x-plane diameter was 3420mm. Percutaneous access was transapical in 10,
retrograde aortic in 2, and direct chest wall puncture in 2 cases. The LVPA ostium was
closed with Amplazter devices in all cases. Large LVPA sacs were ﬁlled with
embolization coils in 3 patients and thrombin injection in 1 patient. 12 of 14 patients
were alive at mean followup of 717467 days. 1 patient had persistent LVPA ﬂow
requiring a second closure at day 447. He had attempted surgical repair of an LVPA to
bronchial ﬁstula and died intraoperatively at day 448. 1 patient died of progressive
CHF at day 741 after CTA at day 642 had shown no residual LVPA ﬂow. 8 of 12
patients with heart failure had improvement of  1 NYHA class (mean change
-0.81.3). 7 patients had followup CTAs 3 months post procedure (mean 24  17
months). 6 of 7 followup CTAs had no residual ﬂow into the LVPA. 1 patient had
residual LVPA ﬂow after 2 closure procedures.
Conclusions: Percutaneous LVPA closure can be performed safely with durable long-
term results. The majority of patients with heart failure symptoms improve after
closure. Followup CTA imaging demonstrates effective exclusion of LVPA ﬂow in
most cases.
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Background: Pulmonary thromboendarterectomy (PEA) has been a standard therapy
for the treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH),
however, up to 40% of patients are considered non-operable due to distal types of
thromboembolism or comorbidities, resulting in poor prognosis. Therefore, we per-
formed balloon pulmonary angioplasty (BPA) for non-operable patients, and evalu-
ated the efﬁcacy of BPA in comparison with PEA.
Methods: We treated 46 CTEPH patients from November 2001 to May 2013.
Operable 21 patients underwent PEA (56.8  14.7 years old, San-Diego class I:9, II:4,
III:8, IV:0) and 25 non-operable patients, with mean pulmonary artery pressureJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstracts/O(mPAP)  25mmHg in spite of under medical therapy, were performed BPA　(67.8 
10.3 years old, San-Diego class I:0, II:3, III:15, IV:7). BPA was repeated in 1 to 6
sessions to every patient depending on their severity. We evaluated hemodynamics by
Swan-Ganz catheter at baseline and post procedure.
Results: PEA signiﬁcantly improved hemodynamics in operable patients (Table). In
non-operable patients, even BPA dramatically improved hemodynamic parameters
such as a signiﬁcant increase in cardiac output (CO) and decrease in mPAP and
pulmonary vascular resistance (PVR), which were accompanied with improved 6-
minute walk distance (6MWD) and WHO-Fc as observed in PEA for operable
patients. Reperfusion pulmonary injury occurred in 3 patients (14.3%) after PEA, and
in 21 sessions (32.8%) after BPA with 3 sessions required emergent intubation. Two
patients (9.5%) died after PEA due to persistent of right heart failure and 1 patient
(4.0%) died after BPA due to systemic infection.Conclusions: BPA could be an effective treatment option for non-operable CTEPH to
achieve dramatic improvement of hemodynamic and outcome parameters. The efﬁ-
cacy and safety for non-operable cases were equivalent to those of PEA for operable
cases.
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Is fetal aortic valvuloplasty effective to achieve a biventricular circulation after
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Background: Critical aortic stenosis (AS) in utero is a severe disease that may evolve
to hypoplastic left heart syndrome (HLHS) if not treated. Fetal aortic valvuloplasty
(AV) has been performed in selected cases to avert this progression. However, more
data is required to assess its impact on achieving a biventricular circulation (BVC),
especially in patients with smaller left ventricles (LV). We report the immediate
procedural results and the postnatal outcomes up to one year of age of fetuses who
underwent AV.
Methods: Procedures were performed under spinal maternal block and fetal anes-
thesia between 23 to 34 weeks gestation through a transabdominal (maternal) and
transthoracic (fetus) approach under echo guidance. The LV apex was entered using
17/18 G Chiba needles and the valve was dilated with coronary angioplasty
balloons (1-1.2 times the valve annulus). Serial echos were performed pre and post
natally.
Results: Thirteen fetuses underwent the procedure. Five were severely hydropic,
4 had severe mitral regurgitation and gigantic left atrium (GLA), 3 had hypoplastic
LVs (2 severe). Endocardial ﬁbroelastosis was present in all (severe in 6). In all but 1
fetus the valve was successfully crossed and dilated. Satisfactory antegrade ﬂow was
observed in 12 cases, aortic insufﬁciency in 7 and pericardial effusion  bradycardia
in 9 fetuses requiring needle aspiration + atropine. There were no maternal compli-
cations. There were 2 early neonatal deaths after premature delivery because of severe
hydrops (both with GLA). BVC was achieved in 3 neonates. All required aortic
valvuloplasty. Three with smaller LV underwent aortic valvuloplasty + hybrid
procedures, with 2 undergoing LV overhaul and a BVC @ 9 months of age. In the
other a BVC is still contemplated. One neonate born at another institution died on
the ﬁrst day of life, 3 were managed as univentricular hearts and 1 had comfort care
(no LV growth).
Conclusions: Fetal aortic valvuloplasty may improve overall neonatal and infancy
outcomes. BVC was achieved in 30% of the cases with a chance of improving to
a 50% rate. Neonatal outcomes seem to depend on the clinical and anatomical fetal
presentation, with hydropic fetuses having worse outcomes.RAL/Percutaneous Treatment of Non-valvular Structural Heart Disease B33
